search
Back to results

Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study (CARGOx)

Primary Purpose

Diabetes Insipidus, Polydipsia, Primary

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Arginine infusion
Hypertonic saline infusion
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetes Insipidus focused on measuring Copeptin

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Hypotonic polyuria / polydipsia syndrome defined as: polyuria >50ml/kg body weight/24h and polydipsia >3l /24h or known diabetes insipidus under treatment with DDAVP
  • Urine-Osmolality <800mOsm/L

Exclusion Criteria:

  • Polyuria / polydipsia secondary to diabetes mellitus, hypercalcemia or hypokalemia
  • Nephrogenic diabetes insipidus (defined as baseline copeptin level >21.4pmol/L)
  • Evidence of any acute illness
  • Epilepsy requiring treatment
  • Uncontrolled arterial hypertension (blood pressure >160/100mmHg at baseline)
  • Cardiac failure (NYHA III-IV)
  • Liver cirrhosis (Child B-C)
  • Uncorrected adrenal or thyroidal deficiency
  • Patients refusing or unable to give written informed consent
  • Pregnancy or breast feeding
  • End of life care

Sites / Locations

  • Hospital das clinicas Minas Gerais
  • University Hospital Würzburg
  • Granda Ospedale Maggiore Policlinico Milan
  • Erasmus MC
  • University Hospital Basel, Department of Endocrinology
  • University Hospital Zurich
  • Cambridge University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arginine Infusion

Hypertonic saline infusion

Arm Description

Arginine Stimulation Test

Hypertonic Saline Infusion Test

Outcomes

Primary Outcome Measures

The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.
For Arginine stimulation the copeptin cut-off to differentiate between diabetes insipidus and primary polydipsia will be 3.8 pmol/l after 60 minutes, for hypertonic saline stimulation it will be the copeptin cut-off 4.9 pmol/l taken at the end of the test

Secondary Outcome Measures

Sensitivity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Specificity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Positive predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation
Accuracy of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Sensitivity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Specificity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Accuracy of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Sensitivity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Specificity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Frequency and severity of thirst assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of headache assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of nausea assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of vertigo assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of general malaise assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Subjective burden assessed by visual analogue scale of both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Health care costs of both tests
Frequency of test preference at follow up visit

Full Information

First Posted
June 4, 2018
Last Updated
July 24, 2023
Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, Wuerzburg University Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, Federal University of Minas Gerais
search

1. Study Identification

Unique Protocol Identification Number
NCT03572166
Brief Title
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
Acronym
CARGOx
Official Title
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
September 3, 2018 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, Wuerzburg University Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, Federal University of Minas Gerais

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The differential diagnosis of central diabetes insipidus (cDI) is difficult and the current test with the highest diagnostic accuracy is copeptin measurement after hypertonic saline infusion (HIS). Although the HIS improved diagnostic accuracy compared to the standard water deprivation test used for decades before, it still comprises great discomfort for patients due to the rise in serum sodium levels above 149mmol/l and requires the presence of medical staff at all times to guarantee safety of the test. The arginine stimulation test is routinely used to stimulate growth hormone. Own data in 52 patients with polyuria / polydipsia syndrome showed that arginine infusion is a potent stimulator of the neurohypophysis and provides a new diagnostic tool in the differential diagnosis of cDI. Copeptin measurements upon arginine stimulation (CAS) discriminated patients with diabetes insipidus vs. patients with primary polydipsia with a high diagnostic accuracy of 94%. To validate these results and to compare them against the HIS a large multicenter trial is needed, where the diagnostic accuracy of the CAS is compared to the HIS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Insipidus, Polydipsia, Primary
Keywords
Copeptin

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Observational randomized cross-over diagnostic international multicenter study
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
177 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arginine Infusion
Arm Type
Experimental
Arm Description
Arginine Stimulation Test
Arm Title
Hypertonic saline infusion
Arm Type
Active Comparator
Arm Description
Hypertonic Saline Infusion Test
Intervention Type
Diagnostic Test
Intervention Name(s)
Arginine infusion
Intervention Description
Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
Intervention Type
Diagnostic Test
Intervention Name(s)
Hypertonic saline infusion
Intervention Description
Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
Primary Outcome Measure Information:
Title
The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.
Description
For Arginine stimulation the copeptin cut-off to differentiate between diabetes insipidus and primary polydipsia will be 3.8 pmol/l after 60 minutes, for hypertonic saline stimulation it will be the copeptin cut-off 4.9 pmol/l taken at the end of the test
Time Frame
2 days
Secondary Outcome Measure Information:
Title
Sensitivity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Positive predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used: Arginine stimulation: Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia Hypertonic saline stimulation: Copeptin level < 2.7 pmol/l = complete central diabetes insipidus Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Accuracy of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Sensitivity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Accuracy of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Sensitivity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Frequency and severity of thirst assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of headache assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of nausea assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of vertigo assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of general malaise assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Subjective burden assessed by visual analogue scale of both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Health care costs of both tests
Time Frame
2 days (1 for each test)
Title
Frequency of test preference at follow up visit
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Hypotonic polyuria / polydipsia syndrome defined as: polyuria >50ml/kg body weight/24h and polydipsia >3l /24h or known diabetes insipidus under treatment with DDAVP Urine-Osmolality <800mOsm/L Exclusion Criteria: Polyuria / polydipsia secondary to diabetes mellitus, hypercalcemia or hypokalemia Nephrogenic diabetes insipidus (defined as baseline copeptin level >21.4pmol/L) Evidence of any acute illness Epilepsy requiring treatment Uncontrolled arterial hypertension (blood pressure >160/100mmHg at baseline) Cardiac failure (NYHA III-IV) Liver cirrhosis (Child B-C) Uncorrected adrenal or thyroidal deficiency Patients refusing or unable to give written informed consent Pregnancy or breast feeding End of life care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mirjam Christ-Crain, Prof, MD
Organizational Affiliation
University Hospital, Basel, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital das clinicas Minas Gerais
City
Belo Horizonte
Country
Brazil
Facility Name
University Hospital Würzburg
City
Würzburg
Country
Germany
Facility Name
Granda Ospedale Maggiore Policlinico Milan
City
Milan
Country
Italy
Facility Name
Erasmus MC
City
Rotterdam
Country
Netherlands
Facility Name
University Hospital Basel, Department of Endocrinology
City
Basel
State/Province
Basel Stadt
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
University Hospital Zurich
City
Zürich
Country
Switzerland
Facility Name
Cambridge University Hospital
City
Cambridge
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study

We'll reach out to this number within 24 hrs